MedTrace Logo

Multinational Haemapheresis Vigilance Study

NCT01576237 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2021-07-22

No results posted yet for this study

Summary

During a seven years period the participating transfusion medicine establishments will report all their non-trivial adverse events (AE) occurring during preparative hemaphereses. Complications may be related to the blood donors, the blood products, the disposables or the apheresis devices. The study hypothesis regarding each participating center is that their procedure-related AE rate is not higher than the respective rate of all other centers in total.

Conditions

  • Blood Donation With Hemapheresis

Interventions

OTHER

blood donation

blood donation with preparative hemapheresis

Sponsors & Collaborators

  • Aix Scientifics

    collaborator INDUSTRY

  • DGTI - Haemapheresis Vigilance Working Party

    lead NETWORK

Principal Investigators

  • Hans-Gert Heuft, PD. Dr. med. · Hannover Medical School (MHH)

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2022-12-31
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01576237 on ClinicalTrials.gov